Research on colorectal and bowel cancer. Covers AI-audited colonoscopy, gut-bacteria links, family risk, and early-onset differences.
Researchers at Vanderbilt University Medical Center have identified a new potential target for preventing colon cancer: the PPARdelta gene. By 'knocking out' this gene in mice, they found that polyp development was inhibited, providing a promising avenue for safer prevention methods.
The American College of Gastroenterology states that colonoscopy is the best and gold-standard test for colorectal cancer screening and prevention. It prevents about 80 percent of colorectal cancers from developing by removing precancerous polyps, while CT colonography has shown poor results in comparison.
Virtual colonoscopy has shown promise as a colorectal cancer screening option, with limitations in detecting flat polyps and varying results in clinical trials. Further research is needed to determine the optimal size for removing small growths and standardizing test performance.
A recent study found that cancer survivors experience significant long-term burdens, including lower quality of life and lost productivity, persisting even beyond 10 years after diagnosis. The burden varies by cancer type, with those diagnosed with shorter-survival cancers reporting greater impacts.
The American Gastroenterological Association disputes the validity of a recent study suggesting that too many surveillance colonoscopies are being performed. The study, published in Annals of Internal Medicine, highlights the importance of determining the clinical significance of small polyps and notes the need for further research to ...
Physicians often recommend more frequent surveillance colonoscopies than recommended guidelines, citing clinical evidence and personal factors as influential. This may lead to unnecessary procedures, affecting quality of care and resource utilization.
A national study led by UC Davis researchers found that surveillance colonoscopies are performed more frequently than necessary, with 24% of gastroenterologists recommending unnecessary procedures. The study suggests that implementation of clinical guidelines can help optimize patient care and reduce healthcare burden.
A study found that physical symptoms, such as shortness of breath and weakness, predict cancer prognosis. Physical health-related quality of life (hrQoL) factors were stronger predictors of survival than psychosocial factors.
A new phase 2 study shows that combining cetuximab with irinotecan can resensitize tumors resistant to irinotecan, offering patients a new treatment option. The study's modest benefits in stopping cancer growth and improving patient response are seen as a step forward in treating colorectal cancer.
Researchers engineered a decoy Met receptor that successfully competes for HGF binding, inhibiting tumor growth and survival. The Sema domain of the Met receptor is also necessary for activation, offering a new therapeutic target for cancer treatment.
Researchers found that higher milk consumption and total calcium intake were associated with a reduced risk of colorectal cancer. The risk decreased with increasing milk consumption, particularly cancers of the distal colon and rectum.
A recent study found that calcium supplementation can slightly decrease the risk of all types of colorectal polyps, with a greater effect on advanced lesions. Additionally, a diet high in fiber and low in fat may enhance this preventive effect.
Researchers found that calcium supplementation slightly decreases the risk of all types of colorectal polyps, with a greater effect on advanced lesions. A diet high in fiber and low in fat also shows promise in increasing the preventive effect of calcium.
A new study demonstrates that Xeloda reduces the risk of colon cancer recurrence (relapse-free survival) by 14% compared to i.v. 5-FU/LV after surgery. The global trial, X-ACT, met its primary endpoint and offers new hope for patients with early stage colon cancer.
A Phase III trial found that CAMPTOSAR combinations with select targeted agents improve survival for MCRC patients. The combination of Avastin and IFL yields an average survival of 25.1 months compared to 15.8 months with IFL alone. A Phase II trial also shows the efficacy of Erbitux plus CAMPTOSAR and infusional FOLFIRI in EGFR-expres...
Dr. Bernard Levin, a colorectal cancer expert, is honored by ASCO for his significant contributions to preventing and managing cancer. He will deliver an acceptance lecture on June 6, highlighting his leadership in multidisciplinary programs in research, service, and education.
The FDA-approved Avastin increases patient survival by almost five months when combined with chemotherapy, showing a 10.6-month progression-free survival rate compared to 6.2 months in the control group.
Researchers found that combining Avastin with chemotherapy improves median survival, reduces risk of death and increases response rates in patients with advanced colorectal cancer. The study showed a nearly five-month improvement in patient survival, demonstrating the potential of targeting tumor blood supply as a viable treatment option.
A UCSF physician argues that blanket screenings can compromise quality patient care, particularly for elderly patients with severe illnesses. She advocates for a more targeted approach to screening, considering a patient's prognosis and preferences.
A randomized clinical trial found that regional and systemic adjuvant chemotherapy regimens had similar survival rates for colon cancer patients, with the combination regimen offering no added benefit. The study, published in the Journal of the National Cancer Institute, also showed lower adverse reaction rates for regional therapy.
A randomized trial found that direct mailing of fecal occult blood tests increased colorectal cancer screening rates by 16.9% among those who received kits and 23.2% among those with reminders, compared to 1.5% for the control group.
A new five-year, $5.6 million NCI grant is supporting a clinical trial to study a blood test for detecting colorectal cancer recurrence based on the protein guanylyl cyclase C (GCC). The trial aims to determine if GCC testing by RT-PCR analysis is more sensitive and specific than current methods in early detection of recurrence.
A study found that heavy alcohol consumption is associated with a slightly increased risk of colorectal cancer. The American College of Physicians task force released eight recommendations to redefine the domain of general internal medicine, suggesting a balance between breadth and depth in practice, as well as team-based care.
Researchers found that African Americans and whites with identical health care coverage experience no racial disparity in colon cancer survival. While subtle differences were seen in treatment options, the study suggests equal access to care can eliminate disparities
Researchers have identified a potential DNA marker, SFRP2, that can be used to detect colorectal cancer in stool samples with high sensitivity and specificity. This breakthrough could lead to earlier detection and treatment of the disease.
A study published in JAMA found that computed tomographic colonography (CTC) had lower sensitivity rates compared to conventional colonoscopy for detecting colorectal tumors, raising concerns about its readiness for widespread clinical use.
A 10-year study found that laparoscopic surgery for colorectal cancer has the same prognosis as conventional surgery, with a 76% 5-year survival rate. The procedure resulted in shorter postoperative recovery times but longer surgery durations compared to conventional surgery.
Two new studies found no association between aspirin use and mortality from pancreatic cancer, while elevated insulin production was linked to an increased risk of colorectal cancer. Hyperinsulinemia, a condition associated with type 2 diabetes, also appears to be linked to an increased risk of colorectal cancer.
A new clinical trial called TREE-2 is evaluating the safety and efficacy of three regimens of ELoxatin as a first-line treatment for patients with metastatic colorectal cancer. The study combines an effective anti-angiogenesis antibody with chemotherapy to improve treatment outcomes.
A new computer-based program, HCCRACT-R, provides personalized colon cancer risk data and helps individuals make informed decisions. The tool, developed by Dr. Weinstein, takes into account both modifiable and unchangeable risk factors, and has been shown to correct misconceptions about risk perception in over 75% of participants.
Researchers have discovered that short-term use of estrogen plus progestin is associated with a decreased incidence of colorectal cancers. However, these cancers are diagnosed at more advanced stages, suggesting further study is needed to understand this phenomenon.
New guidelines have been revised to improve the detection of hereditary nonpolyposis colorectal cancer (HNPCC) by prioritizing MSI testing in patients under 50 and those with family history, reducing risk for cancers associated with specific mutations.
African-Americans are more likely to have advanced stage cancer by the time it's diagnosed, and less likely to receive radiation therapy after surgery. Rectal cancer patients of any race still don't always receive optimal post-surgery care, highlighting a need for further studies to improve treatment guidelines.
A recent study found racial disparities in the delivery of care to black and white rectal cancer patients. Black patients were diagnosed at a younger age and had more advanced disease, leading to differences in treatment outcomes. The study suggests that improved access to state-of-the-art surgical care for minority patients with recta...
A study found that high levels of CRP in blood are associated with an increased risk of colon cancer, particularly in individuals who do not smoke. Elevated CRP concentrations were also found in people with rectal cancer, but the association was weaker.
A study published in The Journal of the American Medical Association found that people with higher CRP levels were more likely to develop colorectal cancers over an 11-year period. Median CRP levels were higher among those who developed colon cancer, and inflammation was linked to increased risk without being mediated by diabetes.
Researchers discuss the need for additional research and standardization in partial-breast irradiation and accelerated partial-breast irradiation. A new study also finds that preoperative chemoradiation may benefit some patients with rectal cancer, while a diet high in glycemic load is linked to an increased risk of colorectal cancer.
The decline in hormone therapy (HT) use was attributed to the release of data from two long-term studies showing that HT did not protect against heart disease and may even increase the risk. The study found that women who took HT had a higher risk for heart disease and breast cancer compared to those who did not take HT.
Activation of the PPAR-delta receptor increases development of precancerous intestinal polyps in mice, with larger polyps being more likely to progress to colorectal cancer. Treatment with a specific compound linked to the receptor may accelerate polyp growth through antiapoptotic pathways.
A study found that sigmoidoscopies are often inadequate in older women, with a significant increase in failures to reach the colon's lower third. The study suggests that age-related factors, such as bowel preparation difficulties and anatomical variations, may contribute to these findings.
Researchers are testing a gene therapy approach called tumor immunization, which involves delivering the IL12 gene to cancer cells to trigger an immune response. The method has shown promise in laboratory and animal studies, with up to 20% of animals experiencing complete tumor eradication.
A recent study found no association between BRCA mutations and an increased risk of colorectal cancer. Researchers tested blood samples from 1,422 patients with colorectal cancer and 1,566 control subjects for mutations in BRCA1 or BRCA2 genes. The results suggest that BRCA mutation carriers do not need to worry about an elevated risk ...
Researchers found no association between BRCA1/2 mutations and colorectal cancer risk in two studies. No increased risk was observed among Ashkenazi Jewish mutation carriers or those with a family history of breast cancer.
Researchers developed a risk index to identify people at higher risk of finding advanced precancerous growths in the upper colon. The study found that older age, being male, and having certain types and sizes of polyps in the lower colon were associated with an increased probability of finding these growths.
The Penn State project aims to create interactive maps of cancer rates in specific geographic areas, enabling better planning and evaluation of cancer interventions. Based on prostate and colorectal cancers, the model can be expanded to other states, utilizing available screenings and interventions to reduce cancer burden.
The study found that men who consumed high amounts of vitamin D, cereal fiber, and took non-steroidal anti-inflammatory drugs were less likely to have serious colon polyps or tumors. Smoking was significantly associated with a higher risk of having a tumor or benign polyps.
Researchers found positive associations between history of first-degree relative, current smoking, and moderate to heavy alcohol use with increased risk of advanced neoplasia. Conversely, higher cereal fiber intake, vitamin D levels, and daily NSAID use were linked to lower risk.
A new study on virtual colonoscopy has shown remarkable improvement in diagnosis but also revealed significant discomfort for patients. Gastrointestinal specialists emphasize the need for verification of results and caution against relying solely on virtual colonoscopy.
Chronic inflammation has been linked to an increased risk of colon cancer, with oxidative stress playing a key role in the development of genetic mutations. Researchers found that DNA damage caused by malondialdehye can lead to frameshift mutations, which may contribute to colorectal cancer.
A study of nearly 2,000 patients found that heavy alcohol consumption was associated with a higher risk of colorectal cancer. Patients with significant spirits intake may benefit from more intensive screening, according to the American College of Gastroenterology.
A Phase III study shows that Avastin, an anti-angiogenic agent, extends patient survival time to 20.3 months when added to first-line chemotherapy. The treatment also improves response rates and duration of response across all relevant patient subgroups.
The Annual Report to the Nation on Cancer statistics shows stabilized cancer rates. A study found carboplatin-paclitaxel is better tolerated in ovarian cancer patients than cisplatin-paclitaxel. Another study linked blood transfusions with HHV-8 seropositivity, while HPV status may predict cervical lesion prognosis
A recent study confirms oxaliplatin's safety in treating advanced colorectal cancer, with low rates of high-grade gastrointestinal side effects. The treatment regimen, combined with fluorouracil and leucovorin, showed improved results in patients who had previously failed first-line chemotherapy.
Research suggests that frequent consumption of miso soup and high intake of isoflavones may lower breast cancer risk. Vitamin D analog paricalcitol also demonstrates antitumor activity against myeloid leukemia, myeloma, and colon cancer cells.
A study of over 78,000 women found that those who worked rotating night shifts for years had a 35% greater risk of developing colorectal cancer. Additionally, research on melanoma suggests two separate pathways may lead to its development, and polymorphisms in certain genes may be associated with prostate cancer risk.
Bevacizumab significantly extends survival time for metastatic colorectal cancer patients by shrinking tumors and inhibiting tumor growth. The study showed a median survival increase of five months compared to standard chemotherapy alone, with significant delays in cancer progression.
A new treatment combination, FOLFOX4, has been shown to delay time-to-tumor progression and provide relief from tumor-related symptoms in patients with progressive metastatic colorectal cancer. The therapy offers an important option for those without other treatment options.
The study found that African Americans in the Appalachian region are 18% more likely to have proximal colon cancer and 56% more likely to have advanced-stage disease. This disparity may be due to screening disparities leading to delayed detection and lower recovery rates.
A new study found that beta-carotene supplementation increased colorectal adenoma recurrence risk among smokers and heavy drinkers. Randomized trials showed a significant decrease in adenoma recurrence risk without smoking or drinking, but paradoxical results when exposed to these lifestyle factors.
Researchers at McGill University discovered a genetic mutation, MTHFR variant, that predicts better response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer patients. The study found 26 out of 43 patients with the variant responded well to chemotherapy.